Sunovion’s discovery, development and commercialization of important therapies to address serious medical conditions, including COPD.
A Decade of Innovation
Within a decade, Sunovion has brought forward several new treatment options to address serious medical conditions that impact the lives of millions of people worldwide. The company’s track record has included making significant advancements in the treatment of serious medical conditions and partnering on educational and advocacy initiatives to empower people living with these conditions.
Lonhala® Magnair® (glycopyrrolate) Inhalation Solution is a medicine called an anticholinergic. LONHALA MAGNAIR is used long term, twice each day (morning and evening), for maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
Please read the full Prescribing Information for Lonhala Magnair.
For HCP Information, please visit: Visit Lonhala Magnair HCP site
For patient information, please visit: Visit Lonhala Magnair patient site
We believe in putting people first, which is why we created Sunovion Answers. Our caring and skilled team is available to provide knowledge and resources to help patients, caregivers, family members, or providers. We’re committed to finding solutions and connecting people to the information they need.
Specialists are available anytime between 8AM and 8PM (ET): 1-855-552-8832